332 related articles for article (PubMed ID: 27556350)
1. Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.
Carcao M; Fukutake K; Inbal A; Kerlin B; Lassila R; Oldenburg J; Garly ML; Nugent D
Semin Thromb Hemost; 2017 Feb; 43(1):59-68. PubMed ID: 27556350
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients.
Williams M; Will A; Stenmo C; Rosholm A; Tehranchi R
Haemophilia; 2014 Jan; 20(1):99-105. PubMed ID: 23834599
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.
Kerlin BA; Inbal A; Will A; Williams M; Garly ML; Jacobsen L; Kearney SL
J Thromb Haemost; 2017 Aug; 15(8):1601-1606. PubMed ID: 28581691
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.
Kerlin B; Brand B; Inbal A; Halimeh S; Nugent D; Lundblad M; Tehranchi R
J Thromb Haemost; 2014 Dec; 12(12):2038-43. PubMed ID: 25263390
[TBL] [Abstract][Full Text] [Related]
5. Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A
Ivaškevičius V; Biswas A; Garly ML; Oldenburg J
Haemophilia; 2017 May; 23(3):e194-e203. PubMed ID: 28520207
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency.
Brand-Staufer B; Carcao M; Kerlin BA; Will A; Williams M; Tornøe CW; Sandberg Lundblad M; Nugent D
Haemophilia; 2015 May; 21(3):380-385. PubMed ID: 25643920
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Ashley C; Chang E; Davis J; Mangione A; Frame V; Nugent DJ
Haemophilia; 2015 Jan; 21(1):102-8. PubMed ID: 25377187
[TBL] [Abstract][Full Text] [Related]
8. Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit.
Tahlan A; Ahluwalia J
Arch Pathol Lab Med; 2014 Feb; 138(2):278-81. PubMed ID: 24476525
[TBL] [Abstract][Full Text] [Related]
9. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement.
Pitkänen HH; Jouppila A; Lemponen M; Ilmakunnas M; Ahonen J; Lassila R
Thromb Res; 2017 Jan; 149():56-61. PubMed ID: 27902939
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency.
Lovejoy AE; Reynolds TC; Visich JE; Butine MD; Young G; Belvedere MA; Blain RC; Pederson SM; Ishak LM; Nugent DJ
Blood; 2006 Jul; 108(1):57-62. PubMed ID: 16556896
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency.
Nugent DJ; Ashley C; García-Talavera J; Lo LC; Mehdi AS; Mangione A
Haemophilia; 2015 Jan; 21(1):95-101. PubMed ID: 25458735
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study.
Zanon E; Pasca S; Sottilotta G; Molinari AC; Ferretti A; Di Gregorio P; Pollio B; Pizzuti M; Notarangelo LD; Biasoli C; Cojutti P; Pea F; Simioni P; Peyvandi F
Blood Transfus; 2023 Jul; 21(4):350-355. PubMed ID: 36580025
[TBL] [Abstract][Full Text] [Related]
13. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.
Carcao M; Altisent C; Castaman G; Fukutake K; Kerlin BA; Kessler C; Lassila R; Nugent D; Oldenburg J; Garly ML; Rosholm A; Inbal A
Thromb Haemost; 2018 Mar; 118(3):451-460. PubMed ID: 29448295
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency.
Inbal A; Oldenburg J; Carcao M; Rosholm A; Tehranchi R; Nugent D
Blood; 2012 May; 119(22):5111-7. PubMed ID: 22451421
[TBL] [Abstract][Full Text] [Related]
15. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice.
Souri M; Koseki-Kuno S; Takeda N; Degen JL; Ichinose A
Int J Hematol; 2008 Jan; 87(1):60-8. PubMed ID: 18224415
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency.
Cojutti PG; Zanon E; Pasca S; Pea F;
Clin Pharmacokinet; 2022 Apr; 61(4):505-513. PubMed ID: 34718987
[TBL] [Abstract][Full Text] [Related]
17. Long-term prophylaxis in patients with severe congenital factor XIII deficiency is not complicated by inhibitor formation.
Naderi M; Ahmadinejad M; Hosseini MS; Moradi E; Dorgalaleh A; Shamsizadeh M
Blood Coagul Fibrinolysis; 2017 Jun; 28(4):276-278. PubMed ID: 27306330
[TBL] [Abstract][Full Text] [Related]
18. Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency.
Wada H; Souri M; Matsumoto R; Sugihara T; Ichinose A
Thromb Haemost; 2013 Apr; 109(4):661-8. PubMed ID: 23407795
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers.
Reynolds TC; Butine MD; Visich JE; Gunewardena KA; MacMahon M; Pederson S; Bishop PD; Morton KM
J Thromb Haemost; 2005 May; 3(5):922-8. PubMed ID: 15869585
[TBL] [Abstract][Full Text] [Related]
20. A child with acquired factor XIII deficiency: case report and literature review.
Kessel R; Hu C; Shore-Lesserson L; Rand J; Manwani D
Haemophilia; 2013 Nov; 19(6):814-26. PubMed ID: 23607876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
